Healing · Peptide Guide

TB-500 tracker

Also known as: Thymosin Beta-4 fragment

Log TB-500 injections and monitor healing cycles with AI Peps.

What is TB-500?

TB-500 is derived from Thymosin Beta-4 and is researched for its systemic (rather than local) healing effects. Protocols often run 4–8 weeks with a loading phase followed by weekly maintenance. AI Peps tracks your loading vs maintenance phase, weekly totals, and injection site rotation.

Common doses

2–5 mg per week (research range)

Frequency

1–2x weekly

Cycle length

4–8 weeks loading, then maintenance

Administration

Subcutaneous or intramuscular injection

Storage

Refrigerate reconstituted vial; use within 60 days

Why track TB-500 in AI Peps

  • ✦Systemic tissue repair
  • ✦Improved flexibility and range of motion
  • ✦Faster recovery from overuse injuries
  • ✦Commonly stacked with BPC-157

Considerations

  • ·Research chemical — not FDA approved for human use
  • ·Loading phase followed by maintenance is common
  • ·Consult a qualified clinician before use

AI Peps is a tracking tool, not medical advice. Always consult a qualified clinician before starting any peptide or GLP-1 protocol.

TB-500 — frequently asked questions

How does AI Peps handle TB-500 loading vs maintenance phases?

AI Peps supports phased protocols. You define a loading dose (e.g. 5 mg weekly) for the first 4 weeks and a maintenance dose (e.g. 2 mg weekly) after — the app automatically transitions and reminds you.

What is the typical TB-500 dose?

Research protocols use 2–5 mg weekly, split into 1–2 injections, for 4–8 weeks. AI Peps ships with TB-500 templates you can tweak.

Track TB-500 the smart way

Download AI Peps free on the App Store — dose logging, cycle tracking, and AI insights for TB-500.

Download on theApp Store

Related peptide guides

Healing

BPC-157

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It is widely researched for its role in tissue repair, tendon and ligament healing, and gut integrity.

GLP-1

Semaglutide

Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

GLP-1

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).